Please ensure Javascript is enabled for purposes of website accessibility

This Spinoff Just Got More Interesting

By Dave Williamson – Updated Apr 7, 2017 at 12:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In this video, senior health-care analyst David Williamson discusses Abbott Labs' recent phase 2 hepatitis C drug results and how they are changing the perception of who will control this multibillion-dollar market. Watch and find out what lays ahead for Abbott, or more specifically its spinoff AbbVie, and the rest of the stocks racing to produce the best-in-class next-gen treatment.

Many investors are attracted to Amarin and biotechs like it since they hold the allure of substantial short-term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.

Dave Williamson, Max Macaluso, and The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Gilead Sciences and Vertex Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Stock Quote
Bristol Myers Squibb
BMY
$79.24 (0.13%) $0.10
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$106.96 (0.89%) $0.94
Achillion Pharmaceuticals Stock Quote
Achillion Pharmaceuticals
ACHN
Gilead Sciences Stock Quote
Gilead Sciences
GILD
$86.26 (0.98%) $0.84
Vertex Pharmaceuticals Stock Quote
Vertex Pharmaceuticals
VRTX
$312.98 (-1.01%) $-3.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.